ArticleScientific reports2026
Primary hepatopancreatobiliary lymphoma: epidemiology, clinical features, and treatment outcomes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differences in the epidemiology, clinical features, and treatment strategies of primary lymphomas of the liver, pancreas, and biliary system (primary hepatopancreatobiliary lymphomas [PHPBL]) remain unclear. We compared the clinical characteristics of patients with lymphomas of these organ systems to facilitate earlier and more effective interventions. We retrospectively analyzed PHPBL data from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2022). We compared the incidence rates, clinical indicators, and subtype distribution differences among the lymphoma subgroups. Propensity score matching (1:1) was applied to balance covariates between chemotherapy and non‑chemotherapy groups. Multivariate Cox regression models were used to identify prognostic factors. Kaplan-Meier survival analysis was performed. We included 2,509 patients with PHPBL. The overall PHPBL incidence showed a significant declining trend [annual percent change: -1.33%], most particularly for primary pancreatic lymphoma. Pathological type distribution varied across primary sites. Diffuse large B-cell lymphoma was most common in primary hepatic lymphoma, followed by follicular lymphoma in primary pancreatic lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma most commonly involved the pancreas. Age, pathological type, primary site, SEER stage, marital status, and surgery or chemotherapy were independent prognostic factors. Subgroup multivariable analyses revealed that chemotherapy was independently associated with improved overall survival (OS) in both primary hepatic lymphoma (PHL) and primary biliary lymphoma (PBL), but cancer‑specific survival (CSS) benefit reached significance only in PHL. After propensity score matching, chemotherapy combined with surgery yielded the best survival outcomes in primary pancreatic lymphoma (PPL). Further analysis of surgery in PPL showed marked heterogeneity by histological subtype: surgery significantly improved OS in follicular lymphoma but not in other subtypes. This study revealed unique epidemiological patterns of PHPBL and emphasized the importance of individualized treatment based on pathological subtypes and primary sites. Chemotherapy should be particularly carefully selected in PHPBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.